Skip to main content
Clinical Trials/ACTRN12621000399897
ACTRN12621000399897
Recruiting
未知

The efficacy of micronutrients as a treatment for emotional dysregulation in teenagers experiencing mood difficulties/problems: A community randomized placebo-controlled trial

Professor Julia Rucklidge0 sites150 target enrollmentApril 9, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Professor Julia Rucklidge
Enrollment
150
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 9, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Professor Julia Rucklidge

Eligibility Criteria

Inclusion Criteria

  • 1\) between 12 and 17 years, 2\) regular access to the internet/phone, 3\) living in New Zealand, 4\) considered reliable and compliant with protocol (including ingestion of as many as 12 capsules/day with food), 5\) be presenting to their GP or school counsellor with functionally impairing emotional dysregulation which cannot be better accounted for by a medical condition or parental identified as showing disabling emotions that are interfering with their ability to function, 6\) sufficient ability to read and write English in order to complete questionnaires, 7\) be attending primary or high school, and 8\) receive a CGI\-S rating of at least 4 (moderately ill) on screening and a minimum score of 10 on the Emotion Dysregulation Inventory or 3 on the Affective Reactivity Index.

Exclusion Criteria

  • 1\) The main strict contraindications are metabolic conditions such as Wilson’s disease (copper), haemochromatosis (iron), phenylketonuira (phenylalanine) and trimethylaminuria (choline), 2\) Known neurological disorders involving brain or other central function (e.g., previously diagnosed intellectual disability, autism spectrum disorder, epilepsy, MS, narcolepsy) or other major psychiatric condition requiring hospitalization (e.g. significant mood disorder with associated suicidality, substance dependence or psychosis), 3\) pregnant or breastfeeding, and 4\) Any medications with primarily central nervous system activity, including psychotropic medication (e.g. SSRIs, tricyclics, benzodiazepines). Participants must have been off these medications for a minimum of four weeks prior to the trial. Participants will not be encouraged to come off a medication in order to participate.

Outcomes

Primary Outcomes

Not specified

Similar Trials